Issue of Equity

Motif Bio plc

("Motif Bio" or the "Company")

Issue of Equity

Motif Bio plc (AIM: MTFB) the clinical stage biopharmaceutical company specialising in developing novel antibiotics announces that it has issued, in aggregate, 409,000 new ordinary shares in the Company ("Ordinary Shares") as part of the terms of the renegotiated Convertible Promissory Notes with Amphion Innovations plc and Amphion Innovations US Inc., as previously announced on 8 September 2016.

Application has been made for the 409,000 new Ordinary Shares to be admitted to trading on AIM ("Admission"), which is expected to occur at 8.00 a.m. on 15 September 2016. The new Ordinary Shares will rank pari passu with the existing Ordinary Shares. Following Admission, and for the purposes of the Disclosure and Transparency Rules, the Company's total issued share capital will consist of 109,010,496 Ordinary Shares. Shareholders may use this figure as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the issued share capital of the Company.

For further information please contact: